Completed PHASE2 INTERVENTIONAL 2-arm NCT04264130

Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection (SACT)

Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection

Sponsor: Centre de Recherche Médicale de Lambaréné

Conditions Schistosomiasis Haematobia

Interventions Artefenomel-Ferroquine Artemether-Lumefantrine Artesunate-Pyronaridine

Updated 4 times since 2020 Last updated: Feb 7, 2020 Started: Jul 31, 2018 Primary completion: Dec 31, 2019 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04264130, this PHASE2 trial focuses on Schistosomiasis Haematobia and remains completed. Sponsored by Centre de Recherche Médicale de Lambaréné, it has been updated 4 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Jul 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre de Recherche Médicale de Lambaréné

Data source: Centre de Recherche Médicale de Lambaréné

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lambaréné, Gabon